Benzinga | Aug 5, 2021 06:09AM EDT

HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $10

HC Wainwright & Co. analyst Edward White maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and lowers the price target from $12 to $10.